CAS: 1029872-54-5 - Vemurafenib
Formula:C23H18ClF2N3O3S
InChI:InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
InChI key:InChIKey=GPXBXXGIAQBQNI-UHFFFAOYSA-N
SMILES:O=C(C1=CNC2=NC=C(C=C21)C=3C=CC(Cl)=CC3)C=4C(F)=CC=C(NS(=O)(=O)CCC)C4F
- Synonyms:
- 1-Propanesulfonamide, N-[3-[[5-(4-Chlorophenyl)-1H-Pyrrolo[2,3-B]Pyridin-3-Yl]Carbonyl]-2,4-Difluorophenyl]-
- N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide
- N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide
- Plx 4032
- Plx-4032 (RG7024)
- Propane-1-sulfonic acid [3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]amide
- Rg 7204
- Ro 51-85426
- Ro 5185426
- Zelboraf
- See more synonyms
- Vemurafenib
N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide
CAS:1029872-54-5
Formula:
C46H35Cl2F4N6O6S2
Purity:
95%
Molecular weight:
978.8363
Ref: IN-DA0035AD
250mg | 150.00 € |
Estimated delivery in United States, on Friday 22 Nov 2024
Plx-4032
CAS:1029872-54-5
Plx-4032 (Vemurafenib) is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Formula:
C23H18ClF2N3O3S
Purity:
99.36% - 99.94%
Color and Shape:
Solid
Molecular weight:
489.92
- Inhibitors
- MAPK
- Raf
- Antineoplastic agents
- See more categories
- Vemurafenib and Impurities
Ref: TM-T8654
10mg | 54.00 € | ||
50mg | 78.00 € | ||
100mg | 97.00 € | ||
200mg | 167.00 € | ||
500mg | 286.00 € | ||
1mL*10mM (DMSO) | 55.00 € |
Estimated delivery in United States, on Friday 29 Nov 2024
PLX 4032
CAS:1029872-54-5
BRAF kinase inhibitor; antineoplastic
Formula:
C23H18ClF2N3O3S
Purity:
Min. 95%
Color and Shape:
Powder
Molecular weight:
489.92 g/mol
Ref: 3D-FV15248
1g | 865.00 € | ||
50mg | 180.00 € | ||
100mg | 218.00 € | ||
250mg | 383.00 € | ||
500mg | 544.00 € |
Estimated delivery in United States, on Tuesday 3 Dec 2024